EGFR and neoplasm: Increased secretion of IL11 by reactive astrocytes, which binds to EGFR and gp130 on tumor cells and activates the downstream AKT signaling, promotes PDL1 expression in EGFR‐mutated NSCLC BM cells and increases apoptosis of T cells in the brain TME, providing a novel therapeutic approach that combined targeting gp130 with EGFR‐TKIs for the treatment of patients with EGFR‐mutant NSCLC BM.